Pharmaceutical Innovation in the Treatment of Schizophrenia and Mental Disorders Compared with Other Diseases

Innovations in Clinical Neuroscience

Emma van Eijndhoven¹  Crystal Henderson¹  Clement Francois¹  Leslie Citrome¹  Joanna P. MacEwan¹  Seth Seabury¹  Siddhesh Kamat¹  Myrlene Sanon Aigbogun¹ 

[1] Dr. MacEwan and Ms. van Eijndhoven are with Precision Health Economics in Los Angeles, California, USA; Dr. Seabury is with the University of Southern California, Los Angeles, California, USA; Ms. Aigbogun, Mr. Kamat, and Dr. Henderson are with Otsuka America Pharmaceutical, Inc. in Princeton, New Jersey, USA; Dr. Francois is with Lundbeck LLC in Deerfield, Illinois, USA; and Dr. Citrome is with the New York Medical College, Valhalla, New York, USA.

关键词: Mental disorders;    schizophrenia;    bipolar disorder;    major depressive disorder;    pharmaceutical innovation;    disease burden;    research and development;    expenditures;   

DOI  :  

学科分类：精神健康和精神病学

来源: Matrix Medical Communications, LLC

【 摘 要 】

Objectives: The objectives of this study were to assess the level of private and public investment in research and development of treatments for schizophrenia and other mental disorders compared to other diseases in order to present data on the economic burden and pharmaceutical innovation by disease area, and to compare the level of investment relative to burden across different diseases.

【 授权许可】

Unknown